doi:10.1016/j.bmc.2022.116814engQuintana, M.Rodriguez-Rius, A.Vellé, A.Vives, S.Sanz Miguel, P.J.Triola, G.Dinuclear silver and gold bisNHC complexes as drug candidates for cancer therapyART-2022-128718We report four dinuclear silver(I) and gold(I) complexes containing two different bidentate N-heterocyclic carbene ligands (bisNHC). One of these complexes 4, shows strong and selective anticancer activity against the human ovarian cancer cell line A2780. Mechanistically, 4 enhances the oxidative stress by stimulating reactive oxygen species production and inhibiting the scavenging activity of thioredoxin reductase. Our findings provide evidence that tuning ligand and electronic properties of metal-NHC complexes can modulate their reactivity and selectivity and it may result in potential novel anticancer drugs.2022http://zaguan.unizar.es/record/11807710.1016/j.bmc.2022.116814http://zaguan.unizar.es/record/118077oai:zaguan.unizar.es:118077info:eu-repo/grantAgreement/ES/DGA-FSE/E42-20Rinfo:eu-repo/grantAgreement/ES/MICINN/RTI2018-096323-B-I00Bioorganic and Medicinal Chemistry 67 (2022), 116814 [8 pp.]by-nc-ndhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/info:eu-repo/semantics/openAccess